{"id":"W2767805413","doi":"10.1016/s1474-4422(17)30378-2","title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Sanofi Genzyme; Seventh Framework Programme; Genentech; Grifols; Ono Pharmaceutical; Mitsubishi Tanabe Pharma Corporation; Teijin Pharma; Prinses Beatrix Spierfonds; Ministry of Health, Labour and Welfare; Pfizer Japan; Shionogi; Argenx; Bayer Yakuhin; Celgene; Ministry of Education, Culture, Sports, Science and Technology; Calithera Biosciences; Union Chimique Belge; Neurocrine Biosciences; Kissei; Boehringer Ingelheim Japan; Teva Pharmaceutical Industries; Myasthenia Gravis Foundation of America; Bayer HealthCare; European Commission; Sanofi; Pfizer; Biogen; Japan Society for the Promotion of Science; GlaxoSmithKline; Bristol-Myers Squibb; CSL Behring; AstraZeneca; Eisai","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Placebo; Internal medicine; Clinical trial; Polyradiculoneuropathy; Randomized controlled trial; Antibody; Polyneuropathy; Intention-to-treat analysis; Physical therapy; Surgery; Pediatrics; Guillain-Barre syndrome; Immunology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008416384,0.0003858526,0.001333762,0.0000892035,0.0004796695,0.00007601976,0.000541679,0.0001665033,0.00003366594],"category_scores_gemma":[0.0007320427,0.0002493881,0.0003822792,0.00006166071,0.0003027703,0.00008588106,0.0001111884,0.0005035864,0.00001885138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001230823,"about_ca_system_score_gemma":0.0003279537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001878456,"about_ca_topic_score_gemma":0.0006093842,"domain_scores_codex":[0.9973023,0.0003294258,0.000694612,0.000553911,0.0001792596,0.0009404756],"domain_scores_gemma":[0.997524,0.0006345776,0.0005244461,0.00114625,0.00006503714,0.0001057501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9879955,0.0003286333,0.0001829992,0.00004371499,0.00008287732,0.001058976,0.0002567866,0.0002045056,0.002863915,0.0002137641,0.0001978293,0.006570472],"study_design_scores_gemma":[0.9644806,0.01084047,0.0001331296,0.00002939239,0.0001688205,0.0004172082,0.00003039919,0.007475117,0.00009258871,0.0002004177,0.01592524,0.0002066508],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979686,0.0008652311,0.00009097458,0.009485116,0.0009761294,0.007673594,0.00002316269,0.00008931294,0.001110536],"genre_scores_gemma":[0.9926952,0.0009195723,0.00002523607,0.002273467,0.00157759,0.00193683,0.00001238356,0.00006348479,0.000496251],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02351496,"threshold_uncertainty_score":0.9999958,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04185788049793177,"score_gpt":0.332183446972469,"score_spread":0.2903255664745372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}